Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on July 31, 2023, with the report date finalized on August 4, 2023. The filing details amendments to existing secured convertible promissory notes with Juvenescence Limited and a subsequent drawdown of funds.
Key Financial Metrics and Obligations
- New Debt Drawdown: On August 1, 2023, the company drew $500,000 under the amended Secured Note.
- Repayment Date: The outstanding principal balance of the Secured Note is due on February 14, 2024.
- Debt Conversion Status: Juvenescence exchanged the $10 million principal of the "$10 Million Secured Note" for AgeX Series B Preferred Stock. Approximately $692,800 in accrued loan origination fees remains payable and convertible into common stock.
- Revenue and Profit: The filing text does not provide revenue, profit, cash flow, or margin data.
Material Changes and Agreements
On July 31, 2023, AgeX entered into two key amendments with Juvenescence Limited:
- Fourth Amendment to Secured Note:
- Extended the "Reverse Financing Condition" deadline to October 31, 2023, permitting borrowing by subsidiary Reverse Bioengineering, Inc.
- Allowed Juvenescence to convert loans into common stock without the "19.9% Cap" restriction if the conversion price equals the "Drawdown Market Prices" rather than a lower market-based price.
- Amendment to $10 Million Secured Note:
- Mirrored the terms of the Fourth Amendment regarding the 19.9% Cap and conversion pricing.
- Established a conversion window ending October 31, 2023. After this date, conversion is permitted only after 90 days following a Qualified Merger or after March 13, 2024.
Outlook, Risks, and Management Commentary
The filing includes standard forward-looking statements regarding potential future events, noting that actual results may differ due to risk factors detailed in periodic SEC reports. Management disclaims any obligation to update these statements. The primary operational focus of this filing is the restructuring of debt terms to facilitate potential equity conversion and extend financing flexibility for the subsidiary.
Investor Verification Checklist
- Verify the exact terms of the "Drawdown Market Prices" and how they impact potential dilution if Juvenescence exercises conversion rights.
- Confirm the status of the "Reverse Financing Condition" and any subsequent borrowing by Reverse Bioengineering, Inc. before the October 31, 2023 deadline.
- Review the full text of the Fourth Amendment (Exhibit 10.1) and the Amendment to the $10 Million Secured Note (Exhibit 10.2) for complete legal terms.
- Monitor the company's liquidity position given the new $500,000 drawdown and the February 14, 2024 repayment obligation.